Clinical Trials · NCT03847207
A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Nxera Pharma UK Limited
- Enrollment
- 42
- Start date
- Jan 2019
- Locations
- 1 site, United Kingdom
- Primary endpoint
- Part 1: Number of treatment related adverse events (as determined by abnormal clinical laboratory tests, vitals signs, ECG parameters, Holter ECG parameters and injection site reactions)